RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

The consensus estimate for Q4 2025 revenue is $24.59 million, and the earnings are expected to come in at -$0.27 per share. The full year 2025's revenue is expected to be $61.58 million and the ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. Recursion Pharmaceuticals stock is charging ahead with explosive momentum.